Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

NCT05201638
clinicaltrials.gov
Phase
Phase 3
clinicaltrials.gov
Recruitment status
Active, not recruiting
clinicaltrials.gov
Participants
1,100
clinicaltrials.gov
Lead sponsor
Immunic AG
clinicaltrials.gov
Start date
2022-01-12
clinicaltrials.gov
Number of sites
76
clinicaltrials.gov

Summary
Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-2)
clinicaltrials.gov
Acronym
ENSURE-2
clinicaltrials.gov
Short title
Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
clinicaltrials.gov
Official title
A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo in Adults With Relapsing Multiple Sclerosis (ENSURE-2)
clinicaltrials.gov

Control arm
Placebo
clinicaltrials.gov
Registry reports results
No
clinicaltrials.gov
Listing at source
Listed
clinicaltrials.gov
Recruitment status
Active, not recruiting
clinicaltrials.gov
Phase
Phase 3
clinicaltrials.gov
Study type
Interventional
clinicaltrials.gov

Completion date
2033-10-01
clinicaltrials.gov
First posted
2022-01-21
clinicaltrials.gov
Registry last updated
2026-02-23
clinicaltrials.gov
Primary completion date
2026-11-01
clinicaltrials.gov
Start date
2022-01-12
clinicaltrials.gov

Actual participants
1,100
clinicaltrials.gov
Participants
1,100
clinicaltrials.gov
Participant count basis
Actual
clinicaltrials.gov
Protocol amendments
1
clinicaltrials.gov
Number of sites
76
clinicaltrials.gov

Registry sponsor category
Industry
clinicaltrials.gov
Lead sponsor
Immunic AG
clinicaltrials.gov
Source registry
ClinicalTrials.gov
clinicaltrials.gov

Registry ID
NCT05201638
clinicaltrials.gov
ClinicalTrials.gov ID
NCT05201638
clinicaltrials.gov
Registry record
Open registry record
clinicaltrials.gov

Allocation
Randomised
Model
Parallel groups
Purpose
Treatment
Masking
Quadruple masking
Masked roles
Participants, Care providers, Investigators, Outcome assessors
Sources for study design
clinicaltrials.gov

  1. To evaluate efficacy of IMU-838 versus placebo based on time to first relapse

    Timeframe: 72 weeks

    Survival analysis of time to first relapse, occurred after the start of study treatment administration and before the end of the double-blind period, censored at a maximum of 72 weeks.

  1. Effect of IMU-838 versus placebo on volume of new T2 lesions

    Timeframe: 72 weeks

    To evaluate the effect of IMU-838 versus placebo on volume of new T2 lesions. Mean difference between IMU-838 and placebo in changes of the volume of new MRI T2 lesions over 24-weeks of treatment in the double-blind period.

  2. Effect of IMU-838 versus placebo on disability progression

    Timeframe: 72 weeks

    To evaluate the effect of IMU-838 versus placebo on disability progression. Survival analysis of time to 12-week confirmed disability progression, as measured on Expanded Disability Status Scale during the double-blind period, censored at maximum 72-weeks.

  3. Effect of IMU-838 versus placebo on cognitive performance

    Timeframe: 72 weeks

    To evaluate the effect of IMU-838 versus placebo on cognitive performance. Survival analysis of time to confirmed clinically relevant changes on Symbol Digit Modalities Test during the double-blind period, censored at maximum 72- weeks.

  4. Effect of IMU-838 versus placebo on whole brain atrophy

    Timeframe: 72 weeks

    To evaluate the effect of IMU-838 versus placebo on whole brain atrophy. Difference in the mean of the percentage change on the whole brain volume between IMU-838 and placebo during the 72-weeks double-blind period.

  5. Safety of IMU-838 versus placebo

    Timeframe: 72 weeks

    To evaluate safety and tolerability by assessment of occurrence of Adverse Events.

Sources for outcomes
clinicaltrials.gov

Sex
All
Age groups
Adults
Minimum age
18 Years
Maximum age
55 Years
Healthy volunteers
No

  • Male or female patient (age ≥18 to ≤55 years).

  • Patients with an established diagnosis of MS according to 2017 McDonald Criteria.

  • Patients with RMS comprising of relapsing remitting MS (RRMS) and active secondary progressive MS, both defined according to Lublin criteria 1996 and 2014.

  • Active disease as defined by Lublin 2014 evidenced prior to Screening by:

    1. At least 2 relapses in the last 24 months before randomization, or
    2. At least 1 relapse in the last 12 months before randomization, or
    3. A positive Gd+ MRI scan (brain and/or spine) in the last 12 months prior to randomization.

  • Willingness and ability to comply with the protocol.

  • Written informed consent given prior to any study-related procedure.

  • Patients with non-active secondary progressive MS and primary progressive MS.
  • Any disease other than MS that may better explain the signs and symptoms, including history of complete transverse myelitis.
  • Clinical signs or presence of laboratory findings suggestive for neuromyelitis optica (NMO) spectrum disorders or myelin oligodendrocyte glycoprotein (MOG)-IgG-associated encephalomyelitis
  • Any active and uncontrolled coexisting autoimmune disease, other than MS (except for type 1 diabetes mellitus and inflammatory bowel disease)
  • Use of experimental/investigational drug (with the exception of COVID-19 vaccines approved by emergency use authorization) and/or participation in drug clinical studies within 6 months prior to Screening
  • Previous or current use of MS treatments lifelong, or within a pre-specified time period.
  • Use of the pre-specified concomitant medications.
  • Clinically significantly abnormal and pre-specified lab values.
  • History of chronic systemic infections within 6 months before the date of informed consent.
  • Diagnosis or suspected liver function impairment, which may cause fluctuating liver function tests during this study.
  • Known history of nephrolithiasis or underlying condition with a strong association of nephrolithiasis.
  • History or clinical diagnosis of gout.
  • History or presence of any major medical or psychiatric illness
  • Substantial medical condition that could create undue risk to the patient, could affect adherence with the study protocol or could undesirably affect study outcomes
Sources for eligibility
clinicaltrials.gov

  • Neuro of Central FloridaAltamonte Springs, United States
  • Healthcare InnovationsCoral Springs, United States
  • Heratsi Hospital Complex 1Yerevan, Armenia
  • Saint Gregory the Illuminator Medical CenterYerevan, Armenia
  • Erebouni Medical CenterYerevan, Armenia
  • UCC of Rep of SrpskaBanja Luka, Bosnia and Herzegovina
  • Bihać, Bosnia and Herzegovina
  • University Clinical Center of SarajevoSarajevo, Bosnia and Herzegovina
  • University Clinical Center SarajevoSarajevo, Bosnia and Herzegovina
  • University Clinical Center TuzlaTuzla, Bosnia and Herzegovina
  • Astra ClinicTallinn, Estonia
  • University Hospital Muenster, Institute Translational Neurology dept. NeurologyMünster, Germany
  • Post-Graduation Institute of Medical Education and Research (PGIMER)Chandigarh, India
  • Fortis Memorial Research InstituteGurugramam, India
  • Polakulath Narayanan Renai Medicity MSSHKochi, India
  • Lucknow, India
  • All India Institute of Medical SciencesNew Delhi, India
  • GB Pant Institute of Postgraduate Medical Education and ResearchNew Delhi, India
  • SRI Guru Ram Das Institute of Medical Sciences and ResearchPunjābi Bāgh, India
  • DKS PGIRaipur, India
  • Hospital Nacional Dos de MayoLima, Peru
  • NZOZ Novo-MedKatowice, Poland
  • NZOZ Wielospecjalistyczna Poradnia Lekarska "Synapsis"Katowice, Poland
  • Neuro-Medic Janusz ZbrojkiewiczKatowice, Poland
  • NZOZ NeuromedLublin, Poland

And 51 more, listed on the interactive page.

Sources for sites
clinicaltrials.gov

Related records

Drugs (1)

Lead sponsors (1)

Conditions (1)

Targets (1)